Literature DB >> 26787281

Breast cancer in 2015: Academic research sheds light on issues that matter to patients.

Martine J Piccart1, Isabelle Gingras2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26787281     DOI： 10.1038/nrclinonc.2015.236

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

2.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Jungsil Ro; Fabrice André; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Cynthia Huang Bartlett; Ke Zhang; Carla Giorgetti; Sophia Randolph; Maria Koehler; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-06-01       Impact factor: 91.245

3.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Authors:  Roberto Salgado; Carsten Denkert; Christine Campbell; Peter Savas; Paolo Nuciforo; Paolo Nucifero; Claudia Aura; Evandro de Azambuja; Holger Eidtmann; Catherine E Ellis; Jose Baselga; Martine J Piccart-Gebhart; Stefan Michiels; Ian Bradbury; Christos Sotiriou; Sherene Loi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

4.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Authors:  Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

5.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

Authors:  Hope S Rugo; William T Barry; Alvaro Moreno-Aspitia; Alan P Lyss; Constance Cirrincione; Eleanor Leung; Erica L Mayer; Michael Naughton; Deborah Toppmeyer; Lisa A Carey; Edith A Perez; Clifford Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

6.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

7.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

8.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

9.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Authors:  G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.